Stability in quarterly activity due to a significant base effect
Strong growth of +57% in bone densitometry activity
Liege (Belgium) –
DMS Imaging
(formerly ASIT Biotech)
(Euronext Brussels and Paris – BE0974289218 – DMSIM)
a French specialist in the development, design and manufacture of imaging systems, publishes its consolidated annual turnover for the 1
er
quarter of fiscal 2022 (period from 1
er
January to March 31, 2022).
Unaudited consolidated data in M€ – IFRS standards | 2019 | 2020 | 2021 |
2022 |
Variation |
Turnover 1 | 6.3 | 7.5 | 8.8 |
8.7 |
-1% |
At 1
er
quarter of fiscal 2022, DMS Imaging sales amounted to €8.7 million, marking the continuation of a solid commercial momentum in the wake of 2021. This start to the year is a good performance, while the 1
er
quarter of 2021 had seen sustained growth of +18% with in particular a high level of invoicing for the Radiology activity. This 1
er
quarter of 2022 is significantly higher than that of the 1
er
quarter of 2020 and the 1
er
quarter 2019.
Samuel Sancerni, Managing Director of DMS Imaging, comments:
”
2020 and 2021 represented two years of strong growth for DMS Imaging despite the pandemic. Thanks to our new production tool – operational since January 2021 – we have been able to significantly improve our production processes and thus increase our added value. In 2022, we will consolidate these new bases by working on the product mix and by stepping up our commercial efforts in mature countries, which traditionally generate more margins. It will also be a year of investment in R&D for DMS Imaging to develop our new solutions which will contribute to turnover from 2024.
»
Comments by activity
The turnover of the activity
Radiology
was down -8% on 1
er
quarter, due to a significant base effect (+18% in the 1
er
quarter of 2021) related to the delivery of a major contract under a World Bank tender during the period last year. The turnover achieved within the framework of distribution agreements, both in Europe and in the United States, is up sharply by just over 30%. The group continued to 1
er
Quarter deliveries of Platinum DRF Adam radiology tables in the United States as part of the partnership with Fujifilm Medical Systems USA
As announced, the group delivered at the end of 1
er
quarter of 2022, its first Platinum Neo radiology table, based on a brand new software platform with the ability to embed machine intelligence and eventually artificial intelligence (AI) functionalities. Its international deployment is expected in 2
n/a
semester.
In
Bone densitometry
activity remained very dynamic in 1
er
quarter of 2022 (+57% growth), in the wake of the end of 2021, still driven by exports and the ramping up of the commercial contract with Fujifilm.
This performance is all the more satisfactory as the delivery schedule for the bone densitometry systems was fully respected on the 1
er
quarter of 2022, first months of in-house manufacturing following the repatriation of production to the new production and assembly unit in Gallargues-le-Montueux.
Contribution of the medical imaging division to DMS Imaging (formerly Asit Biotech)
On January 24, 2022, DMS Group finalized the contribution of its medical imaging division to ASIT Biotech, renamed DMS Imaging on this occasion. The legal, accounting and tax effective date of this contribution is retroactively set at 1
er
January 2022.
DMS Group now holds 88.33% of the capital of DMS Imaging (formerly Asit Biotech), i.e. 1,315,789,473 DMS Imaging shares. These new shares issued as part of the contribution operation will be the subject of a request for admission on the Euronext Growth markets in Brussels and Paris. This admission can only take place after obtaining a visa from the FSMA (Financial Services and Markets Authority – supervisory authority of the Belgian financial sector) on the admission Prospectus currently being prepared.
This prospectus, presenting in particular the 2021 annual accounts of DMS Imaging (formerly Asit Biotech) which will be published at the end of April 2022 as well as a pro forma view, will be filed with the FSMA in the coming weeks for examination.
Outlook
Tensions in terms of supply, particularly for certain electronic components or equipment, remain particularly acute at the start of 2022 but only caused moderate impacts in the 1
er
quarter of 2022, thanks to the agility of the purchasing teams,
supply chain
and group production.
The DMS Imaging division announced in early April the signing of a strategic partnership with the Australian company Micro-X. It will supply DMS Imaging with technological subsystems, including cold cathode X-ray tubes (called Carbon Nano Tube – CNT) and associated generators, which will be integrated into the new mobile radiology solution being developed by Apelem. , a French subsidiary of DMS Imaging, and whose international launch is expected by the end of 2023. This development is part of DMS Imaging’s MC2 project, which aims to develop two new high-end imaging solutions, a radiology and an operating theater arch, which will be manufactured in France. The MC2 project benefits in particular from funding by the French government as part of the Recovery Plan and the Future Investments Program (PIA). These solutions will strengthen DMS Imaging’s product range over the next 24 to 36 months (for more information, read the DMS Imaging press release of April 4, 2022).
Exhibition of activities in Russia, Ukraine and Belarus
Revenue generated in Russia, Ukraine and Belarus was €1.5 million in 2021, representing 4% of revenue for the last financial year (€36.2 million).
DMS Group has no production site or employee exposed to this area, and does not make any direct purchases with suppliers in these countries.
Financial diary 2022
|
Date |
Event |
|
April 29, 2022 | Publication of 2021 annual results |
|
July 20, 2022 | Publication of 2022 half-year revenue |
|
September 30, 2022 | Publication of 2022 half-year results |
|
October 20, 2022 | Publication of the turnover of 3 |
|
January 20, 2023 | Publication of 2022 annual revenue |
The publications will take place after the closing of the Euronext Paris market. These dates are given as an indication, they are likely to be modified if necessary.
About DMS Imaging
(formerly ASIT biotech)
Specialized in high technology in the service of medical diagnosis, DMS Imaging is now positioned as the French leader in the development, design and manufacture of imaging systems dedicated to radiology, bone densitometry, 3D modeling and posturology.
DMS Imaging is listed on the Euronext market in Brussels and Paris (ISIN: BE0974289218 – ticker: DMSIM).
More information on www.asitbiotech.com.
contacts
DMS Imaging
Samuel SANCERNI | General director | +33 4 67 50 49 00 |
Delphine de COURSON | CFO | +33 4 67 50 49 00 |
FINANCE NEWS
Mathieu OMNES | Investor Relations | +33 1 53 67 36 92 |
Fatou-Kine N’DIAYE | Press relations | +33 1 53 67 36 34 |
This post has the “? Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
lZudZ5RolJjKmp5wYZyYa2KZm5tpxWCUa2mZlGZsaJeabGpmlWdlb5qaZnBllWlr
– To check this key:
https://www.security-master-key.com.
Regulated information:
Inside information:
– Other press releases
Full and original press release in PDF format:
https://www.actusnews.com/news/74045-dms-imaging_cp_ca-t1-2022_20042021-en.pdf
© Copyright Actusnews Wire
Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com